Drug Profile
Research programme: methylcarbapenems - Banyu
Alternative Names: Anti-MRSA carbapenems research programme - Banyu; Metylcarbapenems research programme - BanyuLatest Information Update: 13 Mar 2008
Price :
$50
*
At a glance
- Originator Banyu
- Class Carbapenems
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 13 Mar 2008 No development reported - Preclinical for Bacterial infections in Japan (unspecified route)
- 13 Mar 2008 No development reported - Preclinical for Meticillin-resistant Staphylococcus aureus infections in Japan (unspecified route)
- 09 Jan 2002 Preclinical development for Bacterial infections in Japan (unspecified route)